| Subject: | FDA Issues Warning About Remicade (Infliximab) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 21 Oct 2004 - 10:00 am |
| The FDA and Centocor Inc., have issued a warning regarding malignancies associated with the use of Remicade (Infliximab) a TNF-alpha blocking agent used in the treatment of rheumatoid arthritis and Crohn's disease. Remicade works by blocking the body's immune system overproduction of a protein (TNF-alpha), which is an underlying cause of both rheumatoid arthritis and Chron's disease. Remicade also helps to relieve the pain associated with both of these diseases.
It has been discovered that in... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
